Brief: Landos Biopharma Expects To Enter Phase 1 Trial Of Potential Lupus Treatment In Q4
15/09/2021 12:22
Sept 15 (Reuters) - Landos Biopharma Inc LABP.O :
* LANDOS BIOPHARMA TO PRESENT RESULTS OF LABP-104 IN LUPUS
AT THE
AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE 2021
* LANDOS BIOPHARMA - EXPECTS TO ENTER PHASE 1 CLINICAL
TESTING OF
LABP-104 AS AN ORAL THERAPEUTIC CANDIDATE FOR LUPUS DURING Q4 OF
2021
Source text for Eikon: ID:nGNX5Dv4nD
Further company coverage: LABP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Landos Biopharma
See all newsLandos Biopharma Inc expected to post a loss of 100 cents a share - Earnings Preview
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Super Micro, Micron Technology, Navios Maritime
U.S. STOCKS ON THE MOVE-Landos Biopharma, Foot Locker, US energy sector
Brief: AbbVie To Acquire Landos Biopharma